Advances in resistant hypertension.
作者信息
Calhoun David A
机构信息
Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, Alabama, USA.
出版信息
Ann Transl Med. 2018 Aug;6(15):294. doi: 10.21037/atm.2018.07.21.
Abstract
摘要
相似文献
1
Advances in resistant hypertension.顽固性高血压的进展
Ann Transl Med. 2018 Aug;6(15):294. doi: 10.21037/atm.2018.07.21.
2
Recent advances in the management of resistant hypertension.
F1000Prime Rep. 2015 Jan 5;7:03. doi: 10.12703/P7-03. eCollection 2015.
3
Advances in the Pathogenesis and Treatment of Resistant Hypertension.耐药性高血压的发病机制与治疗进展。
Int J Mol Sci. 2023 Aug 18;24(16):12911. doi: 10.3390/ijms241612911.
4
Management of Resistant Hypertension Based on Recommendations from Different Guidelines and the Systolic Blood Pressure Intervention Trial.基于不同指南及收缩压干预试验建议的难治性高血压管理
Cureus. 2019 Aug 12;11(8):e5371. doi: 10.7759/cureus.5371.
5
Recent advances in understanding and managing resistant/refractory hypertension.难治性/顽固性高血压的认识与管理的最新进展
F1000Res. 2020 Mar 9;9. doi: 10.12688/f1000research.21669.1. eCollection 2020.
6
Revision on Renal Sympathetic Ablation in the Treatment of Resistant Hypertension.肾脏交感神经消融术治疗顽固性高血压的研究进展
Curr Hypertens Rev. 2016;12(1):68-86. doi: 10.2174/1573402111666150630140718.
7
Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension.测量肾素/醛固酮水平的临床价值：优化未控制/抵抗性高血压的管理。
Curr Vasc Pharmacol. 2017;16(1):10-14. doi: 10.2174/1570161115666170426145612.
8
When blood pressure refuses to budge: exploring the complexity of resistant hypertension.当血压顽固不降时：探索顽固性高血压的复杂性。
Front Cardiovasc Med. 2023 Jun 21;10:1211199. doi: 10.3389/fcvm.2023.1211199. eCollection 2023.
9
Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure.颈动脉压力感受器刺激治疗高血压抵抗和心力衰竭。
Curr Hypertens Rep. 2012 Jun;14(3):238-46. doi: 10.1007/s11906-012-0258-7.
10
Renal denervation: a new therapeutic approach for resistant hypertension.肾去神经支配：一种治疗顽固性高血压的新方法。
Chin Med J (Engl). 2014;127(18):3302-8.
引用本文的文献
1
Recent advances in understanding and managing resistant/refractory hypertension.难治性/顽固性高血压的认识与管理的最新进展
F1000Res. 2020 Mar 9;9. doi: 10.12688/f1000research.21669.1. eCollection 2020.
2
Global perspectives on cardiometabolic risk and cardiovascular disease: from basic science to bedside.心血管代谢风险与心血管疾病的全球视角：从基础科学到临床应用
Ann Transl Med. 2018 Aug;6(15):290. doi: 10.21037/atm.2018.07.28.
本文引用的文献
1
Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes.难治性高血压并非归因于心血腔容量确定的血管内液潴留。
Hypertension. 2018 Aug;72(2):343-349. doi: 10.1161/HYPERTENSIONAHA.118.10965. Epub 2018 Jun 4.
2
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.耐药性高血压的内分泌和血液动力学变化，以及螺内酯或阿米洛利对血压的反应：PATHWAY-2 机制子研究。
Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8. Epub 2018 Apr 11.
3
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2017美国心脏病学会/美国心脏协会/美国医师协会/美国心脏病学学会/美国预防医学学院/美国老年病学会/美国药剂师协会/美国血液学会/美国预防医学学会/美国医学协会/美国初级保健医师学会成人高血压预防、检测、评估和管理指南：美国心脏病学会/美国心脏协会临床实践指南工作组报告
Hypertension. 2018 Jun;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13.
4
Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial.明显难治性高血压患者的药物依从性：SYMPATHY 试验的结果。
Br J Clin Pharmacol. 2018 Jan;84(1):18-24. doi: 10.1111/bcp.13402. Epub 2017 Oct 10.
5
Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement.因血压测量不准确导致的假性难治性高血压的患病率。
J Am Soc Hypertens. 2016 Jun;10(6):493-9. doi: 10.1016/j.jash.2016.03.186. Epub 2016 Mar 30.
6
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.螺内酯与安慰剂、比索洛尔及多沙唑嗪对比以确定难治性高血压的最佳治疗方案（PATHWAY-2）：一项随机、双盲、交叉试验
Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20.
7
Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure.顽固性高血压：交感神经活动增强作为抗高血压治疗失败原因的证据
Hypertension. 2015 Jul;66(1):126-33. doi: 10.1161/HYPERTENSIONAHA.115.05449. Epub 2015 May 18.
8
Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.基于社区实践网络中诊室血压的明显治疗抵抗性高血压患者的最佳治疗方案的流行率。
Hypertension. 2013 Oct;62(4):691-7. doi: 10.1161/HYPERTENSIONAHA.113.01448. Epub 2013 Aug 5.
9
Clinical characteristics of patients with resistant hypertension: the RESIST-POL study.耐治疗高血压患者的临床特征：RESIST-POL 研究。
J Hum Hypertens. 2013 Nov;27(11):678-85. doi: 10.1038/jhh.2013.32. Epub 2013 May 23.
10
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.难治性高血压：诊断、评估与治疗。美国心脏协会高血压研究理事会专业教育委员会的科学声明。
Hypertension. 2008 Jun;51(6):1403-19. doi: 10.1161/HYPERTENSIONAHA.108.189141. Epub 2008 Apr 7.
Zotero 插件